Panacea Biotec secured a Letter of Award from UNICEF to supply bivalent Oral Polio Vaccine (bOPV). The order, valued at approximately ₹78.24 crore, is for execution in calendar year 2028, reinforcing its role under a long-term agreement.
Panacea Biotec Secures ₹78.24 Crore UNICEF Vaccine Order
Panacea Biotec has received a Letter of Award from UNICEF for supplying bivalent Oral Polio Vaccine (bOPV). Order value: ~₹78.24 crore (US$8.205 million), for execution in CY2028. Reader Takeaway: Consistent UNICEF business provides revenue visibility; execution in 2028 offers long-term contract stability. ## What just happened Panacea Biotec Ltd announced it has received a Letter of Award (LoA) from UNICEF. The award is for the supply of bivalent Oral Polio Vaccine (bOPV) in 10 and 20 dose presentations. The order is valued at approximately ₹78.24 crore (US$8.205 million). This supply is scheduled for execution during the calendar year 2028. ## Why this matters This order signifies continued business from a major international health organization, providing predictable revenue. It validates Panacea Biotec's capability to meet global vaccine supply needs. The specific timeframe for execution in 2028 offers forward-looking revenue visibility within the company's existing contractual framework. ## The backstory The current award operates under a previously announced Long-Term Agreement (LTA) with UNICEF. This LTA covers the supply of bOPV and commenced on April 1, 2026, with an end date of March 31, 2030. The current LoA is a direct continuation and allocation under this existing LTA. ## What changes now This award confirms a specific revenue stream for Panacea Biotec in 2028. It reinforces the company's ongoing supply relationship with UNICEF for essential vaccines. Investors can anticipate this order contributing to the company's financial performance in the designated execution year. ## Risks to watch No specific risks or related party transactions have been disclosed by the company in relation to this award. Standard operational and execution risks common to large supply contracts would apply.
